See more : Biodesix, Inc. (BDSX) Income Statement Analysis – Financial Results
Complete financial analysis of Marrone Bio Innovations, Inc. (MBII) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Marrone Bio Innovations, Inc., a leading company in the Agricultural Inputs industry within the Basic Materials sector.
- Dala Energi AB (publ) (DE.ST) Income Statement Analysis – Financial Results
- Silicom Ltd. (SILC) Income Statement Analysis – Financial Results
- Biofrontera AG (0DOL.L) Income Statement Analysis – Financial Results
- Public Joint-stock Company TNS energo Mari El (MISB.ME) Income Statement Analysis – Financial Results
- ICDS Limited (ICDSLTD.BO) Income Statement Analysis – Financial Results
Marrone Bio Innovations, Inc. (MBII)
About Marrone Bio Innovations, Inc.
Marrone Bio Innovations, Inc. discovers, develops, and sells biological products for crop protection, crop health, and crop nutrition. Its products include Emergen, Foramin, Foramin ST, Optima, Takla, Pacesetter, Ympact, UBP, and UBP ST for increasing crop health, yield, and quality; Grandevo, a bioinsecticide that controls sucking and chewing insects through feeding; Haven, a plant health product to reduce sun stress and dehydration; Jet-Ag and Jet-Oxide peroxyacetic acid sanitizers that prevent, suppress, eliminate, and control algae, fungi, and bacterial diseases in agriculture and horticultural industries; and Majestene, a bionematicide to control soil-dwelling nematodes and certain soil borne insects. The company also offers Regalia and Stargus, which protects against fungal and bacterial diseases and enhances yields/quality; Venerate, a bioinsecticide that controls chewing and sucking insects and mites; and Zelto, a bionematicide that protects turf, including golf course fairways and greens, and promotes turf health by enhancing plant and root health. It provides its products directly through sales force, as well as through distributors and other commercial partners. The company formerly known as Marrone Organic Innovations, Inc. Marrone Bio Innovations, Inc. was incorporated in 2006 and is headquartered in Raleigh, North Carolina.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 44.31M | 100.00K | 29.37M | 21.22M | 18.17M | 14.04M | 9.80M | 9.14M | 14.54M | 7.14M | 5.25M |
| Cost of Revenue | 17.06M | 40.00K | 13.26M | 10.91M | 10.53M | 9.52M | 9.26M | 9.44M | 10.74M | 4.33M | 2.17M |
| Gross Profit | 27.25M | 60.00K | 16.11M | 10.31M | 7.64M | 4.52M | 545.00K | -302.00K | 3.81M | 2.81M | 3.08M |
| Gross Profit Ratio | 61.49% | 60.00% | 54.86% | 48.60% | 42.05% | 32.19% | 5.56% | -3.31% | 26.18% | 39.31% | 58.64% |
| Research & Development | 12.08M | 30.00K | 14.03M | 10.66M | 10.82M | 9.67M | 13.50M | 19.28M | 17.81M | 12.74M | 9.41M |
| General & Administrative | 0.00 | 75.00K | 30.07M | 19.16M | 19.81M | 18.51M | 26.50M | 28.95M | 15.02M | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 30.57M | 75.00K | 30.07M | 19.16M | 19.81M | 18.51M | 26.50M | 28.95M | 15.02M | 0.00 | 0.00 |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.29M | 6.79M |
| Operating Expenses | 42.65M | 105.00K | 44.10M | 29.82M | 30.63M | 28.18M | 40.00M | 48.23M | 32.83M | 23.04M | 16.20M |
| Cost & Expenses | 59.71M | 145.00K | 57.36M | 40.72M | 41.16M | 37.70M | 49.26M | 57.67M | 43.57M | 27.37M | 18.38M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 1.00K | 37.00K | 51.00K | 59.00K | 49.00K | 16.00K | 22.00K |
| Interest Expense | 1.57M | 4.00K | 1.47M | 2.51M | 7.73M | 7.30M | 4.36M | 2.91M | 6.00M | 2.47M | 88.00K |
| Depreciation & Amortization | 4.57M | 3.56M | 3.15M | 1.89M | 2.04M | 2.24M | 3.51M | 2.58M | 976.00K | 613.00K | 499.00K |
| EBITDA | -10.37M | 3.51M | -32.53M | -15.82M | -21.15M | -21.53M | -35.86M | -46.17M | -21.52M | -35.72M | -12.59M |
| EBITDA Ratio | -23.41% | 3,509.00% | -110.75% | -74.53% | -116.43% | -153.35% | -365.83% | -505.37% | -147.95% | -500.21% | -239.82% |
| Operating Income | -14.94M | -17.20M | -27.99M | -19.50M | -23.00M | -23.66M | -39.46M | -48.53M | -29.03M | -23.84M | -13.12M |
| Operating Income Ratio | -33.71% | -17,195.00% | -95.27% | -91.91% | -126.58% | -168.49% | -402.58% | -531.23% | -199.58% | -333.87% | -249.93% |
| Total Other Income/Expenses | -1.57M | 17.14M | -9.19M | -709.00K | -7.93M | -7.41M | -4.27M | -3.13M | 536.00K | -14.96M | -56.00K |
| Income Before Tax | -16.51M | -53.00K | -37.18M | -20.21M | -30.93M | -31.07M | -43.73M | -51.66M | -28.49M | -38.79M | -13.18M |
| Income Before Tax Ratio | -37.26% | -53.00% | -126.56% | -95.25% | -170.23% | -221.27% | -446.16% | -565.44% | -195.89% | -543.33% | -251.00% |
| Income Tax Expense | 45.00K | 17.15M | 15.00K | 1.80M | -201.00K | -109.00K | 92.00K | -219.00K | 6.53M | -12.49M | 32.00K |
| Net Income | -16.55M | -53.00K | -37.18M | -20.21M | -30.93M | -31.07M | -43.73M | -51.66M | -28.49M | -38.79M | -13.18M |
| Net Income Ratio | -37.36% | -53.00% | -126.56% | -95.25% | -170.23% | -221.27% | -446.16% | -565.44% | -195.89% | -543.33% | -251.00% |
| EPS | -0.09 | 0.00 | -0.32 | -0.20 | -1.06 | -1.26 | -1.79 | -2.32 | -3.26 | -2.12 | -0.72 |
| EPS Diluted | -0.09 | 0.00 | -0.32 | -0.20 | -1.06 | -1.26 | -1.79 | -2.32 | -3.20 | -2.12 | -0.72 |
| Weighted Avg Shares Out | 174.83M | 148.89M | 117.98M | 101.25M | 29.24M | 24.62M | 24.47M | 22.31M | 8.73M | 18.27M | 18.27M |
| Weighted Avg Shares Out (Dil) | 174.83M | 148.89M | 117.98M | 101.25M | 29.24M | 24.62M | 24.47M | 22.31M | 8.91M | 18.27M | 18.27M |
Marrone Bio Innovations' (MBII) CEO Kevin Helash on Q2 2021 Results - Earnings Call Transcript
Marrone Bio Innovations, Inc. (MBII) Reports Q2 Loss, Lags Revenue Estimates
Marrone Bio Innovations: Q2 Earnings Insights
Marrone Bio Innovations, Inc. Reports Second-Quarter 2021 Financial Results
Marrone Bio and partner Rizobacter expand strategic alliance to supply Rizonema seed treatment in Brazil
Marrone Bio leading the charge toward more environmentally-conscious effective pest management for farmers
Marrone Bio strikes partnership with ATP Nutrition to distribute Stargus Biofungicide on Canadian broad-acre crops
Marrone Bio Innovations Partners with ATP Nutrition to Distribute Stargus® Biofungicide in Canada
Marrone Bio Innovations' (MBII) CEO Kevin Helash on Q1 2021 Results - Earnings Call Transcript
Marrone Bio Innovations, Inc. (MBII) Reports Q1 Loss, Misses Revenue Estimates
Source: https://incomestatements.info
Category: Stock Reports